Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is partly to continue the good experience the investigators have
with chemotherapy and partly to optimize treatment of inoperable cholangiocarcinoma by adding
a biological antibody to the treatment of patients with wild-type Kirsten rat sarcoma viral
oncogene homolog (KRAS).